RT Journal Article
SR Electronic
T1 Immunotherapy by Gene Transfer with Plasmids Encoding IL-12/IL-18 is Superior to IL-23/IL-18 Gene Transfer in a Rat Osteosarcoma Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2861
OP 2867
VO 24
IS 5A
A1 CHRISTIAN LIEBAU
A1 CHRISTIAN ROESEL
A1 SEBASTIAN SCHMIDT
A1 CHRISTIAAN KARREMAN
A1 JOHANNES BERND PRISACK
A1 HANS BOJAR
A1 HARRY MERK
A1 NEUMANN WOLFRAM
A1 AXEL W.A. BALTZER
YR 2004
UL http://ar.iiarjournals.org/content/24/5A/2861.abstract
AB Background: Osteosarcomas are primary malignant tumors of bone or soft parts arising from bone-forming mesenchymal cells. Despite dramatic therapeutic advances, namely neo-adjuvant and adjuvant chemotherapy, progress is at a plateau. Cytokine-mediated gene therapy might represent a further advance in the therapy of the osteosarcoma. Materials and Methods: We transfected UMR 108 osteosarcoma cells with different plasmids encoding IL-12, IL-23, proIL-18 and ICE (Interleukin-converting enzyme). IFN-γ induction, which is known to induce antitumor effects mediated by the immune system, and cytotoxic effects of various cytokine combination were investigated. Results: Our results show that local secretion of IL-12 by UMR 108 cells led to an induction of cytotoxic effects mediated by mononuclear cells, which were enhanced by additional administration of recombinant IL-18. In contrast to IL-18, IL-23 showed a moderate increase of IFN-γ induction when transfected alone and could only slightly increase the IFN-γ induction mediated by IL-12. IL-18 enhanced IFN-γ induction when applied alone and was able to increase the IFN-γ production that was induced by IL-12. Conclusion: IL-23 seems to be a less effective immuno-therapeutic for adjuvant treatment of osteosarcomas than IL-12 and IL-18, when taking only IFN-γ induction into consideration. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved